Related Experiment Videos
Heptavalent pneumococcal conjugate vaccine: current and future impact
Katherine K Hsu1, Stephen I Pelton
1Boston University Medical Center, Section of Pediatric Infectious Diseases, 774 Albany Street, Finland Labs 5th Floor, Boston, MA 02118-2393, USA. khsu@bu.edu
Expert Review of Vaccines
|January 9, 2004
Summary
The heptavalent pneumococcal conjugate vaccine (PCV7) prevents invasive pneumococcal disease in young children. This review covers PCV7
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae causes significant global morbidity and mortality.
- It is the leading cause of invasive bacterial disease in children in Hib-vaccinated populations.
- Pneumococcal conjugate vaccine (PCV7) development spans over five decades.
Purpose of the Study:
- Review safety, immunogenicity, and efficacy studies for PCV7 approval.
- Summarize post-licensure childhood pneumococcal disease incidence in the USA.
- Examine current PCV7 treatment guidelines and future research directions.
Main Methods:
- Review of safety, immunogenicity, and efficacy studies.
- Analysis of epidemiological data on childhood pneumococcal disease.
- Compilation of treatment guidelines from multiple countries.
Main Results:
- PCV7 demonstrated safety, immunogenicity, and efficacy, leading to FDA approval.
- Post-licensure data indicates a reduction in invasive pneumococcal disease.
- Current guidelines exist for PCV7 use and treatment.
Conclusions:
- PCV7 is a critical tool for preventing childhood pneumococcal disease.
- Continued surveillance and research are essential for optimizing pneumococcal disease control.
- Vaccine development has significantly impacted pediatric infectious disease burden.